Patents Assigned to Centre Regional de Lutte Contre le Cancer-Centre Francois Baclesse
  • CANCER THERAPY USING Bcl-XL-SPECIFIC siNA
    Publication number: 20130237584
    Abstract: The invention relates to a double-stranded short interfering nucleic acid (siNA) molecule specific to the Bcl-XL transcript, comprising a sense and an antisense region, wherein the sense region comprises the nucleotide sequence SEQ ID NO: 1 or a sequence having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with said sequence, and the antisense region comprises a nucleotide sequence that is complementary to the sense region, and its use for treating cancer.
    Type: Application
    Filed: May 15, 2012
    Publication date: September 12, 2013
    Applicant: CENTRE REGIONAL DE LUTTE CONTRE LE CANCER - CENTRE FRANCOIS BACLESSE
    Inventors: Laurent Poulain, Pascal Gauduchon, Emilie Brotin, Ester Saison-Behmoaras
  • Cancer therapy using Bcl-X-specific siNA
    Patent number: 8193333
    Abstract: The invention relates to a double-stranded short interfering nucleic acid (siNA) molecule specific to the Bcl-XL transcript, comprising a sense and an antisense region, wherein the sense region comprises the nucleotide sequence SEQ ID NO: 1 or a sequence having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with said sequence, and the antisense region comprises a nucleotide sequence that is complementary to the sense region, and its use for treating cancer.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: June 5, 2012
    Assignee: Centre Regional de Lutte Contre le Cancer-Centre Francois Baclesse
    Inventors: Laurent Poulain, Pascal Gauduchon, Emilie Brotin, Ester Saison-Behmoaras
  • CANCER THERAPY USING BCL-XL-SPECIFIC SINA
    Publication number: 20090312393
    Abstract: The invention relates to a double-stranded short interfering nucleic acid (siNA) molecule specific to the Bcl-XL transcript, comprising a sense and an antisense region, wherein the sense region comprises the nucleotide sequence SEQ ID NO: 1 or a sequence having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with said sequence, and the antisense region comprises a nucleotide sequence that is complementary to the sense region, and its use for treating cancer.
    Type: Application
    Filed: June 22, 2007
    Publication date: December 17, 2009
    Applicant: CENTRE REGIONAL DE LUTTE CONTRE LE CANCER - CENTRE FRANCOIS BACLESSE
    Inventors: Laurent Poulain, Pascal Gauduchon, Emilie Brotin, Ester Saison-Behmoaras